Net Income

With a key depression drug nearing Phase 3 and more data imminent, AtaiBeckley is set to make its case to Wall Street at three major March conferences.

With a massive dataset from $6.2B in prior authorizations, SamaCare's AI is speeding up access to critical drugs, but raises questions about market power.

Citing 'prolonged underperformance,' activist investor Starboard Value seeks to replace Tripadvisor's board, igniting a battle for control.

Brunswick Exploration launches a new drill program at a major Quebec lithium find, part of a global strategy in a surging market for critical minerals.

Despite a $70M net loss and falling sales, chemical firm Orion S.A. highlights positive free cash flow and a new focus on financial discipline.

As Pasithea Therapeutics heads to a key investor conference, all eyes are on its lead drug, PAS-004, and its potential to treat rare and complex diseases.

Zefiro Methane founder accuses the board of entrenchment tactics, setting the stage for a critical BCSC hearing that will shape the company's future.

A strategic merger creates a new aerospace and defense giant, but existing shareholders face significant dilution in a deal laden with both promise and risk.

Two small businesses from Pennsylvania are finding massive success in Asia, leveraging Coupang's AI-powered platform to bypass traditional export hurdles.

As global leaders gather in Mumbai, the focus shifts from climate negotiation to concrete action, testing new tools to accelerate progress toward COP31.

Montréal defied a turbulent year, welcoming 11.8M visitors and securing $5.8B in spending. Now, it's gearing up for its biggest year since the Olympics.

A new global championship aims to unify competitive barbecue, offering a $1M prize and a path from local cook-offs to a Las Vegas world final.

As BRC Inc. preps its 2025 earnings report, can its new energy drink line and veteran mission overcome inflation, lawsuits, and declining margins?

Knife River reports a record Q4 and $1B backlog, fueled by acquisitions. But a 22% drop in annual net income reveals the high cost of its expansion.

A second real-world study finds an FDA-approved device brings significant relief to over 80% of tinnitus patients, offering new hope for millions.

The fintech giants are launching integrated expense cards with cashback rewards, aiming to turn business spending into a source of savings for European CFOs.

Forget simple indicators. A new breed of retail trader uses complex data, automation, and strict risk rules to gain a professional edge in the market.

With a bolstered cash runway from recent funding, Inventiva is all-in on its MASH drug, lanifibranor, racing against giants in a multi-billion dollar market.

A key partnership, backed by the Saskatchewan government, is pioneering advanced DLE technology to unlock Canada's vast lithium brine resources for the EV market.

A Swedish biotech and Belgian university secure major EU funding to advance a first-in-class drug against glioblastoma, a notoriously deadly brain tumor.